ESH Video

2nd Translational Research Conference: Acute Lymphoblastic Leukaemia

2nd Translational Research Conference: Acute Lymphoblastic Leukaemia
May 07 - May 09, 2021 - E-CONFERENCE, #ESHALL2021
Chairs : Jan Cools, Hervé Dombret, Adele Fielding, Mark Litzow


CONFERENCE UPDATE: novel coronavirus (COVID-19)

ESH 2nd Translational Research Conference
Acute Lymphoblastic Leukaemia: MOVING ONLINE

May 7-9, 2021
Chairs: Jan Cools, Hervé Dombret, Adele Fielding, Mark Litzov


In view of continuing COVID-19 related challenges and uncertainties, ESH has decided to hold the 2nd Translational Research Conference on ALL as a virtual event.

REGISTRATION IS OFFERED FREE OF CHARGE as a gesture of solidarity during these difficult times.

The E-Conference will welcome an outstanding faculty of global authorities for a scientific programme that is designed to integrate leading-edge basic, clinical and therapeutic advances, and new perspectives.

Registered participants will further benefit from opportunities for informal scientific interaction with the world’s leading experts in the field during closed Meet the Expert sessions and E-Mentored Posters Walks.

Participants will be joining us from all over the world and from different time zones. To make sure that everyone has access to the full scientific programme at a convenient hour, registration will allow participants to join both the LIVE PROGRAMME  and the PROGRAMME ON DEMAND.

– The “Live Programme” is to be found on programme page. It will be streamed live CET time, as indicated. It will include lectures, roundtable discussions, Meet the Expert sessions, interactive panel discussions, voting and Q&A periods, and Mentored Poster Walks. It will also include some pre-recorded lectures that will be streamed live, followed by their corresponding fully live Q&A period.

– The “Programme on Demand” available as of April 27, 2021, will initially include the pre-recorded components of the scientific programme. It will be progressively enriched by the meeting’s live, interactive components which will be recorded real time during the meeting.

The Virtual platform will remain open from April 27 until June 9, 2021 so that participants can view and review the programme’s full scientific content at times convenient to them.

We have selected a platform with the technical capacity and environment which we feel responds to ESH objectives in terms of learning, scientific interaction and conviviality.

We hope that you will be interested in joining us for this ESH E-Conference on ALL,

In the meantime Stay Safe!
The ESH Team



Major recent advances in the knowledge of the biological underpinning of acute lymphoblastic leukaemia (ALL) include the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, the identification of new potentially druggable disease subsets and the discovery of predisposing, preleukaemic events. 

 At the same time, the clinical management of the disease has improved in both children and adults thanks to the routine monitoring of measurable residual disease (MRD), the administration of intensified risk-adapted chemotherapy, the introduction of targeted therapies and antibodies, and the remarkable efficacy of antibody-drug conjugates (ADCs), bi-specific T-cell engager antibodies (BiTEs) and manufactured chimeric antigen receptor (CAR) T-cells.

This intense research activity has led to major improvements in patient outcome, while also providing important proofs of concept for the treatment of cancer in general. It has also made ALL a fascinating disease to study.

Submitted abstracts will be considered for presentation as Brief Oral Communications or Posters. Opportunities for exchange with the faculty include face-to-face live discussions during closed Meet the Expert sessions and during the plenary Mentored Poster Walks.

A strong emphasis will be placed on scientific discussion and debate throughout the meeting.


Upon completion of this CME activity, participants should have:

– improved their understanding of how to optimally diagnose and classify ALL by combining modern diagnostic algorithms and early MRD monitoring for the rapid delivery of the right treatment to the right patient;

– an overview of conventional therapeutic options, with a focus on the role of allogeneic haemopoietic stem cell transplantation;

– learned how to optimize the management of individual patients on the basis of individual drug metabolism, tolerance and toxicity;

– improved their knowledge of new, emerging targeted or immunological treatments and understand how they may be combined or how they could eventually replace current conventional treatment options.



– Biology of B-cell precursor ALL
– Biology of T-cell ALL
– Minimal residual disease monitoring
– Individualized management of ALL
– New advances in ALL
– Car T-cells & allogeneic HSCT
– Frontline incorporation of BiTEs and ADCs
– T-cell ALL and lymphoblastic lymphoma
– Ph and PH-like ALL.



  • Plenary Sessions
  • Panel Discussions
  • Debates
  • Poster Walks
  • Meet the Expert Sessions
  • Keynote lectures


Click here to access the updated programme


"Role of HSCT in Ph+ ALL" with Oliver Ottmann & Hervé Dombret
Saturday, May 8th at 10:30 CEST

"Monitoring L-asparaginase Efficacy in ALL Patients" with Mathilde Hunault & Adele Fielding
Saturday, May 8th at 10:30 CEST

"CAR T-cells : Practical Issues" with Nicolas Boissel & Shannon Maude
Sunday, May 9th at 13:00 CEST

"MRD Issues" with Monika Brüggemann & Jan Zuna
Sunday, May 9th at 13:00 CEST

"Allogenic SCT in ALL: Open issues" with David Marks & Mark Litzow
Sunday, May 9th at 13:00 CEST

"Optimal use of BiTEs" with Nicola Gökbuget & Matthew Wieduwilt
Sunday, May 9th at 13:00 CEST

Limited seats! Register now:

Abstract submission



Abstracts are eligible to be selected for an oral or a poster presentation.


  • Your abstract can be structured (eg Objectives, Methods, Results, Conclusions) or unstructured. 
  • Maximum number of words: 500 
  • Your abstract will be submitted to peer review.




The E-Conference platform is open, visit it now: 

Corporate partners

With the support of*:



Level 2 E-Conference Partners



*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.




Educational Grants


The registration fee for the ESH 2nd Translational Research e-Conference on Acute Lymphoblastic Leukaemia is free.

Meet the Expert sessions:  Registration fee:  20€
These sessions are open to E-Conference academic biologists and clinicians registrants only. A maximum of 30 seats are available in each session and pre-registration will therefore be required.
Limited seats! Register now!

Register HereMeet the Expert registration